DHCR7 Activators

The compounds listed above fall into the category of DHCR7 activators due to their potential influence on the cholesterol synthesis pathway. This classification encompasses a diverse group of compounds, including statins such as Lovastatin, Simvastatin, Pravastatin, Atorvastatin, and Rosuvastatin, which inhibit HMG-CoA reductase, an enzyme upstream of DHCR7 in the cholesterol synthesis pathway. By altering the availability of its substrate, these statins may indirectly influence DHCR7 activity.

Furthermore, compounds like Mevalonate, Squalene, Lanosterol, 24,25-Dihydrolanosterol, 7-Dehydrodesmosterol, and 7-Dehydrocholesterol, which are intermediates or substrates in the cholesterol synthesis pathway, could potentially stimulate DHCR7 indirectly. Their increased availability may promote the activity of DHCR7 by providing more substrate for the enzyme to convert into cholesterol. Conversely, U18666A, an inhibitor of cholesterol synthesis and intracellular trafficking, may indirectly affect DHCR7 activity. By inhibiting the synthesis and trafficking of cholesterol, this compound may alter the cellular environment in a way that indirectly influences DHCR7.